Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03140969 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
A Phase 1 study, sponsored by Laboratoires Thea.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03140969 is a Phase 1 study that has completed, run by Laboratoires Thea. The registered enrollment target is 11 participants.
The verdict
NCT03140969, a Phase 1 study, has completed, sponsored by Laboratoires Thea.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
Interventions
- DRUG QR-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03140969
The ClinicalTrials.gov registry entry for NCT03140969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QR-110 is the first listed.
NCT03140969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03140969 about?
NCT03140969 is a clinical study titled "Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene". The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
What is the current status of trial NCT03140969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-10-16. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT03140969?
The interventions under investigation include: QR-110 (DRUG).
Who is sponsoring clinical trial NCT03140969?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.